JAN 13, 2021 6:00 AM PST

Antibodies Gain the Upper Hand Against Sly Tumors

WRITTEN BY: Tara Fernandez

Tumors use ingenious approaches to stay just out of reach of immune cells on patrol and avoid detection. For instance, cancer cells at the periphery of the tumor have been shown to secrete a cocktail of chemicals that creates an impenetrable barrier to immune cells. By suppressing the immune system, these tumor factors interfere with antigen-presenting cells such as macrophages and block the production of tumor-specific T lymphocytes. Beyond the reach of the immune patrol, tumor cells continue to multiply uncontrollably.

Scientists have developed several therapeutic countermeasures to overcome this tumor-induced immune suppression—treatments that, at least in theory, bear tremendous potential. Unfortunately, when it comes to real-world clinical outcomes, many of these immunotherapies have missed the mark. For instance, some studies show that more than half of patients fail to respond to checkpoint blockade therapy as a means of overriding tumors’ immune suppression.

Now, cancer immunologists from the University of Southampton have added a promising new immunotherapy that’s destined to boost oncologists’ tumor-fighting arsenal: an antibody that targets an immune molecule called OX40. The results were published in the Journal for Immunotherapy of Cancer.

OX40 is predominantly expressed in a subset of T cells called Treg cells—specialized immune cells that regulate immune activity. Tregs have been observed to be prevalent around the outer border of tumor tissues, suppressing immune activity in this tumor microenvironment. The new antibody therapy binds specifically to OX40, inactivating Tregs and allowing other immune effectors to enter the scene and begin tumor destruction.

Antibody and vaccine experts Mark Cragg and Jane Willoughby, who led the study, also found that by swapping the antibody isotype, or the region which determines the antibody’s effector function, their new therapy was a potent activator of killer T cells. This triggered a powerful and sustained immune response against the malignant tissues.

"Clinical trials with anti-OX40 antibodies have shown that the body can tolerate these drugs but unfortunately have also shown disappointing clinical responses,” said Cragg. “We need to understand why this is.”

This study provides a means of overcoming these long-standing clinical challenges. "This new data shows us that when there is a cancer with lots of Tregs we could use the equivalent of the m2IgGa isotype and in patients where we feel we need better cytotoxic T cells we could use the equivalent of a mIgG1 isotype to boost the immune response. 

“This information is important for developing the next generation of OX40 antibodies that we hope will be more effective in treating patients with cancer," Cragg added.

While this OX40 antibody therapy continues down the path towards the clinic, a combination of immunotherapeutic agents will likely provide better outcomes for cancer patients. For example, some preclinical studies have shown that a combo of anti-OX40 together with anti-CTLA-4 antibodies boosted the numbers of activated CD4+ and CD8+ T cells in the tumor microenvironment. This provided better outcomes compared to administering anti-OX40 as a monotherapy.

 

 

Sources: Journal for Immunotherapy of Cancer, Cancer Immunol Res, EurekAlert.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
DEC 07, 2020
Cell & Molecular Biology
An Autoimmune Link to Heart Disease is ID'ed
DEC 07, 2020
An Autoimmune Link to Heart Disease is ID'ed
CNIC researchers have found that there is an autoimmune link to cardiovascular disease that may improve diagnostic and t ...
JAN 27, 2021
Drug Discovery & Development
Do Vaccines Work Against New Covid Variants?
JAN 27, 2021
Do Vaccines Work Against New Covid Variants?
The SARS-CoV-2 virus is mutating faster than scientists previously thought. As such, pharmaceutical companies are now sc ...
FEB 09, 2021
Immunology
Putting the Kibosh on HIV's Stealth Tactics
FEB 09, 2021
Putting the Kibosh on HIV's Stealth Tactics
The human immunodeficiency virus or HIV is always one step of the immune system, a tactic that makes it impossible to co ...
FEB 10, 2021
Immunology
Cross-Reactive Antibodies Don't Protect Against COVID
FEB 10, 2021
Cross-Reactive Antibodies Don't Protect Against COVID
Did you know that hundreds of viruses can cause the common cold? Rhinovirus, adenovirus, and coronavirus infections can ...
MAR 07, 2021
Genetics & Genomics
Tuberculosis Influenced the Human Genome
MAR 07, 2021
Tuberculosis Influenced the Human Genome
Throughout human history, our species has come into contact with both harmless and infectious microbes that have changed ...
APR 01, 2021
Immunology
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
APR 01, 2021
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
Cancer researchers have developed a therapeutic vaccine for melanoma, a deadly form of skin cancer. Instead of protectin ...
Loading Comments...